Residual hazard assessment related to handling of antineoplastic drugs: Safety system evolution and quality assurance of analytical measurement

Annals of the New York Academy of Sciences

Volumn 1076, Issue , 2006, Pages 649-656

  Turci, Roberta ^a   Minoia, Claudio ^a  

^a IRCCS   (Italy)

Author keywords

Antineoplastic drugs; Biological monitoring; Environmental monitoring; Occupational exposure; Quality assurance

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DAUNORUBICIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; IDARUBICIN; METHOTREXATE; PLATINUM;

ANALYTIC METHOD; CONFERENCE PAPER; DRUG DETERMINATION; DRUG MONITORING; ENVIRONMENTAL MONITORING; HAZARD ASSESSMENT; HEALTH SURVEY; OCCUPATIONAL EXPOSURE; PERFORMANCE MEASUREMENT SYSTEM; QUALITY CONTROL; RISK ASSESSMENT; UNCERTAINTY;

EID: 33845625637     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1371.047     Document Type: Conference Paper

References (23)

1. FALCK, K. et al. 1979. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet i: 1250-1251.
2. CLINICAL ONCOLOGICAL SOCIETY OF AUSTRALIA. 1983. Guidelines and recommendations for safe handling of antineoplastic agents. Med. J. Aust. 1: 426-428.
3. AMERICAN SOCIETY OF HOSPITAL PHARMACISTS. 1990. ASHP technical assistance bulletin on handling cytotoxic and hazardous drugs. Am. J. Hosp. Pharm. 47: 1033-1049.
4. GUIDELINES FOR THE HANDLING AND DISPOSAL OF HAZARDOUS PHARMACEUTICALS (INCLUDING CYTOTOXIC DRUGS). 1993. Canadian Society of Hospital Pharmacists. Ottawa, Ontario, Canada.
5. OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION. 2000. OSHA Technical Manual. Hospital Investigations: Health Hazard. Section VI http://www.osha-slc. gov/SLTC/hazardousdrugs/index.html.
6. NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (NIOSH). 2004. Preventing Occupational Exposure to Antineoplastic and other Hazardous Drugs in Healthcare Settings. NIOSH Publication No. 2004-165, September 2004 www.cdc.gov/niosh/docs/2004-165.
7. PROVVEDIMENTO 5 AGOSTO. 1999. Documento di linee-guida per la sicurezza e la salute dei lavoratori esposti a chemioterapici antiblastici in ambiente sanitario, G.U. 236, 7.10.1999.
8. TURCI, R. et al. 2003. Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents: a review of analytical methods. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 789: 169-209.
9. SOTTANI, C. et al. 1998a. High-performance liquid chromatography tandem mass spectrometry procedure with automated solid phase extraction sample preparation for the quantitative determination of paclitaxel (Taxol®) in human plasma. Rapid Commum. Mass Spectrom. 12: 251-255.
10. SOTTANI, C. et al. 1998b. Liquid-liquid extraction procedure for trace determination of cyclophosphamide in human urine by high-performance liquid chromatography tandem mass spectrometry. Rapid Commum. Mass Spectrom. 12: 1063-1068.
11. MINOIA, C. et al. 1998. Application of high performance liquid chromatography/tandem mass spectrometry in the environmental and biological monitoring of health care personnel occupationally exposed to cyclophosphamide and ifosfamide. Rapid Commum. Mass Spectrom. 12: 1485-1493.
12. TURCI, R. et al. 2000. Determination of methotrexate in human urine at trace levels by solid phase extraction and high-performance liquid chromatogram/tandem mass spectrometry. Rapid Commum. Mass Spectrom. 14: 173-179.
13. TURCI, R. et al. 2000. Determination of methotrexate in environmental samples by solid phase extraction and high performance liquid chromatography: ultraviolet or tandem mass spectrometry detection? Rapid Commum. Mass Spectrom. 14: 685-691.
14. MICOLI, G. et al. 2001. Determination of 5-fluorouracil in environmental samples by solid-phase extraction and high performance liquid chromatography with ultraviolet detection. J. Chromatogr. B. 750: 25-32.
15. SOTTANI, C. et al. 2000. Rapid and sensitive determination of paclitaxel (Taxol®) in environmental samples by high-performance liquid chromatography tandem mass spectrometry. Rapid Commum. Mass Spectrom. 14: 930-935.
16. TURCI, R. et al. 2002. Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents. Toxicol. Lett. 134: 57-64.
17. SOTTANI, C. et al. 2004a. Validated procedure for simultaneous trace level determination of the anti-cancer agent gemcitabine and its metabolite in human urine by high-performance liquid chromatography with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 18: 1017-1023.
18. SOTTANI, C. et al. 2004b. Trace determination of anthracyclines in urine: a new high-performance liquid chromatography/tandem mass spectrometry method for assessing exposure of hospital personnel. Rapid Commun. Mass Spectrom. 18: 2426-2436.
19. SOTTANI, C. et al. 2005. Highly sensitive high-performance liquid chromatography/selective reaction monitoring mass spectrometry method for the determination of cyclophosphamide and ifosfamide in urine of health care workers exposed to antineoplastic agents. Rapid Commun. Mass Spectrom. 19: 2794-2800.
20. SPEZIA, S. et al. 2005. Comparison of inductively coupled plasma mass spectrometry techniques in the determination of platinum in urine: quadrupole vs. sector field. Rapid Commun. Mass Spectrom. 19: 1551-1556.
21. EURACHEM GUIDE. 1998. The Fitness for Purpose of Analytical Methods. Eurachem, 1st ed. LGC. Teddington, UK. www.eurachem.ul.pt
22. EURACHEM/CITAC GUIDE. 2000. Quantifying Uncertainty in Analytical Measurement, 2nd ed. www.eurachem.ul.pt/
23. INTERNATIONAL AGENCY FOR RESEARCH ON CANCER. 2004. Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Pharmaceutical Drugs. IARC. Lyon, France. www.iarc.fr